DIAMONDBACK DRUGS OF DELAWARE, L.L.C. – Trademark Portfolio

Entity Type: 16

DIAMONDBACK DRUGS OF DELAWARE, L.L.C. has 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO). Filings span 4 Nice Classification classes, led by Class 35 (Advertising & Business) and Class 10 (Medical Apparatus). This trademark owner is based in SCOTTSDALE, AZ.

7631 EAST INDIAN SCHOOL ROAD

SCOTTSDALE, AZ 85251

5 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

DIAMONDBACK DRUGS OF DELAWARE, L.L.C.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

35
Advertising & Business (2 filings)

Advertising; business management; business administration; office functions

10
Medical Apparatus (2 filings)

Surgical, medical, dental and veterinary apparatus and instruments

44
Medical Services (2 filings)

Medical services; veterinary services; hygienic and beauty care for human beings or animals

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does DIAMONDBACK DRUGS OF DELAWARE, L.L.C. have?

DIAMONDBACK DRUGS OF DELAWARE, L.L.C. has 5 U.S. trademarks filed with the USPTO.

What trademark classes does DIAMONDBACK DRUGS OF DELAWARE, L.L.C. file in?

DIAMONDBACK DRUGS OF DELAWARE, L.L.C. files trademarks across 4 Nice Classification classes. The most active classes are Class 35 (Advertising & Business), Class 10 (Medical Apparatus), Class 44 (Medical Services), Class 5 (Pharmaceuticals). Class 35 covers advertising; business management; business administration; office functions.

What is DIAMONDBACK DRUGS OF DELAWARE, L.L.C.'s trademark registration success rate?

DIAMONDBACK DRUGS OF DELAWARE, L.L.C. has a 0% trademark registration rate, with 0 out of 5 resolved applications resulting in successful registration. Currently, 0 applications are pending review.